

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward: NHI:

Palbociclib (Ibrance)

INITIATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has unresectable locally advanced or metastatic breast cancer
and
 - There is documentation confirming disease is hormone-receptor positive and HER2-negative
 - Patient has an ECOG performance score of 0-2
and
 - Disease has relapsed or progressed during prior endocrine therapy
 - or**
 - Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state
 - and**
 - Patient has not received prior systemic treatment for metastatic disease
and
 - Treatment must be used in combination with an endocrine partner
 - and**
 - Patient has not received prior funded treatment with a CDK4/6 inhibitor
or
 - Patient has an active Special Authority approval for ribociclib
 - and**
 - Patient has experienced a grade 3 or 4 adverse reaction to ribociclib that cannot be managed by dose reductions and requires treatment discontinuation
 - and**
 - Treatment must be used in combination with an endocrine partner
 - and**
 - There is no evidence of progressive disease since initiation of ribociclib

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Treatment must be used in combination with an endocrine partner
and
 - There is no evidence of progressive disease since initiation of palbociclib

I confirm that the above details are correct:

Signed: Date: